Search alternatives:
decrease therapeutic » increased therapeutic (Expand Search), degrader therapeutics (Expand Search), great therapeutic (Expand Search)
high resistance » host resistance (Expand Search)
decrease high » decreased hiv (Expand Search), decrease i (Expand Search)
Showing 81 - 100 results of 12,758 for search '(( ((decrease therapeutic) OR (novel therapeutic)) research ) OR ( decrease high resistance ))', query time: 0.75s Refine Results
  1. 81
    Table_1_Reduced Growth of Staphylococcus aureus Under High Glucose Conditions Is Associated With Decreased Pentaglycine Expression.DOC

    Table_1_Reduced Growth of Staphylococcus aureus Under High Glucose Conditions Is Associated With Decreased Pentaglycine Expression.DOC by Zhen Luo (281825)

    Published 2020
    “…Cells of S. aureus from the culture medium with glucose had a thinner cell wall and highly resistant to lysostaphin compared with the bacteria cultured in LB medium. mRNA expression of genes encoding pentaglycine bridges, the substrate of lysostaphin, was significantly decreased in S. aureus by glucose. …”
    Save to List
    Saved in:
  2. 82
    Supplemental Figure S2 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients

    Supplemental Figure S2 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients by Yuna Guo (780568)

    Published 2023
    Save to List
    Saved in:
  3. 83
    Supplemental Figure S3 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients

    Supplemental Figure S3 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients by Yuna Guo (780568)

    Published 2023
    Save to List
    Saved in:
  4. 84
    Supplemental Figure S1 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients

    Supplemental Figure S1 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients by Yuna Guo (780568)

    Published 2023
    Save to List
    Saved in:
  5. 85
    Supplemental Figure S8 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients

    Supplemental Figure S8 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients by Yuna Guo (780568)

    Published 2023
    Save to List
    Saved in:
  6. 86
    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 87
    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  8. 88
    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 89
    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  10. 90
    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells

    Novel DNA Aptamer for CYP24A1 Inhibition with Enhanced Antiproliferative Activity in Cancer Cells by Madhu Biyani (12427332)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  11. 91
    Supplementary Table S15 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution

    Supplementary Table S15 from A Functional Survey of the Regulatory Landscape of Estrogen Receptor–Positive Breast Cancer Evolution by Iros Barozzi (15113515)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 92
    Figure 5 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

    Figure 5 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma by Khaled Mohamed Nassar (19810317)

    Published 2025
    Save to List
    Saved in:
  13. 93
    Figure 3 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

    Figure 3 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma by Khaled Mohamed Nassar (19810317)

    Published 2025
    Save to List
    Saved in:
  14. 94
    Figure 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma

    Figure 1 from PELP1 Is a Novel Therapeutic Target in Hepatocellular Carcinoma by Khaled Mohamed Nassar (19810317)

    Published 2025
    Save to List
    Saved in:
  15. 95
    Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  16. 96
    Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  17. 97
    Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  18. 98
    Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  19. 99
    Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  20. 100
    Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:

Search Tools: